Space Travel News  
EPIDEMICS
Significant progress made towards AIDS vaccine: US official

AIDS funding cuts a death sentence for millions, MSF warns
Vienna (AFP) July 15, 2010 - Cutbacks in rich-world funding for AIDS treatment could sentence millions of sufferers to death for lack of access to anti-retroviral (ARV) drugs, Medecins Sans Frontieres warned Thursday. "Donors have started to shift their support away from HIV/AIDS, and funding is not keeping up with the need," the medical charity warned in a report ahead of a major AIDS conference in Vienna next week. "If nothing is done, most of (those infected with HIV) will die within the next few years," it said, in a study based on fieldwork in eight African countries. According to MSF, many donors have frozen their contribution to the fight against AIDS -- partly due to the financial crisis -- with the United States planning to cut its support for ARV drugs in Mozambique by 15 percent over the next four years. The Global Fund to Fight AIDS, TB and Malaria is trying to raise 20 billion dollars (15.5 billion euros) for the next three years.

So far it has received just a few hundred million dollars, the author of the report, Mit Philips, told journalists. "It is a very frustrating feeling to see that in spite of the achievements that have been made... the international donors, for the moment, show less interest and less resolve to continue to support the fight against HIV/AIDS," she said. "It's as if they want to give up the fight halfway through. We want to tell them: 'you cannot turn back now on AIDS treatment, it's too important'." While some three million HIV patients now have access to anti-retroviral drugs in Africa, the continent worst affected by the virus, another six million were still without treatment, MSF warned. By reducing funding, donor countries would ensure that even less patients received care, or received it too late, it added in its report.

Turning people away from clinics, for lack of staff or resources, would also destroy the sense of trust that took years to build with local communities and make people less willing to come forward and get tested in a region where HIV still carries a strong stigma. MSF's study showed that early and sustained treatment of HIV patients had born fruit in several regions, including Malawi's Thyolo district where the overall death rate dropped by a stunning 37 percent between 2000 and 2007, thanks to universal access to ARVs. Where patients get treatment, "there is an overall reduction of mortality in the community, there is also less tuberculosis and we start to see, where there is a high coverage of ARV, also a reduction in the number of new cases (of HIV/AIDS)," said Philips.
by Staff Writers
Washington (AFP) July 14, 2010
After decades of trying to develop a vaccine against AIDS, global health authorities are finally beginning to make "significant advances" towards their goal, Anthony Fauci, head of the US institute of infectious diseases, told AFP.

"Up to a few years ago, even though we have been trying for a couple of decades to develop a vaccine, unsuccessfully, we have not even had a small clue that we were going in the right direction," Fauci told AFP.

But two key events that have taken place in the past few years have changed that and led to "significant advances in the development of a vaccine," said Fauci, who is head of the National Institute for Allergy and Infectious Disease (NIAID).

The first of those key turning-point events was a clinical trial of an HIV/AIDS vaccine which was conducted last year in Thailand on 16,000 people.

"The results showed a small to modest positive effect on the acquisition of HIV -- not good enough to be able to distribute a vaccine but good enough to tell us that it was a conceptual advance that at least makes us feel now that a vaccine is possible," Fauci said.

Then, last week, scientists at NIAID published a paper in the journal Science about research that had helped them to identify two antibodies in an HIV-positive individual, which, when put together "block 90 percent" of HIV strains, Fauci said.

"What that is telling us is that you can identify the portion of the virus that you would like to use as a vaccine, because we know that when the antibodies bind to that portion, it knock down the virus," he said.

The next step will be to try to inject that part of the virus into an individual to produce a protective response against HIV infection, said Fauci in an interview with AFP days before the 18th international conference on AIDS, to be held in Vienna, Austria.

The Thai study and the report in Science have left scientists feeling "much more confident that ultimately we will have a vaccine" against HIV/AIDS, although it was still impossible to say exactly when that would be, said Fauci.

An AIDS vaccine was probably several years away, which means that in the meantime, the fight against HIV/AIDS must continue to focus on prevention and use tried and true tactics such as condom distribution, male circumcision, blocking mother-to-baby transmission and offering syringe exchange programs, he said.

Ways have to be found, too, to improve access to these preventive measures, especially in developing countries where only 20 percent of "populations who would benefit" actually have access to them, he added.

Along with improving access to the preventive methods, Fauci urged global health authorities and governments to continue to work to develop other forms of prevention, such as microbicides.

And he recommended "treating as many people as we possibly can because we know that when you treat more people, you lessen the probability that they would infect other people.

"You could almost have what we call treatment as a form of prevention," until a vaccine is finally developed, said Fauci.

HIV/AIDS: Factfile
Paris (AFP) July 15, 2010 - Following is a factfile ahead of the 18th International AIDS Conference, running in Vienna from July 18-23:

WHAT IS AIDS? Acquired Immune Deficiency Syndrome, which first came to light in 1981, is the term for a progressive weakening of the immune system. The body is exposed to pneumonia, tuberculosis, fungal disease and other opportunistic infections, as well as specific types of cancer, that ultimately are fatal.

WHAT CAUSES IT? The cause of AIDS is the human immunodeficiency virus (HIV), a retrovirus suspected to have leapt the species barrier from animal primates in central Africa. HIV is found in blood, semen, vaginal secretions and breast milk. It enters the body through cuts or sores or by directly infecting cells in the mucous membranes in the genitals or anus. The main modes of infection are unprotected sexual intercourse, shared use of drug syringes, from a mother to her unborn child and transfusion of contaminated blood.

HOW DOES HIV WORK? HIV destroys key white-blood cells called T-helper lymphocytes. It does this by latching onto a molecule known as CD4 on the cell's surface. The virus then penetrates the cell, hijacking its enzyme-making machinery in order to replicate itself. Baby viruses then burst out to infect other T cells.

HOW LONG DOES IT TAKE? The time from initial infection to full-blown AIDS in untreated patients is about nine years, but the time can vary according to the individual. From AIDS to death generally takes between six months and three years.

WHAT IS THE TOLL? At least 25 million people have been killed by AIDS since the disease came to light in 1981. According to the UN agency UNAIDS, at the end of 2008, around 33.4 million people were living with HIV, 22.4 million of them in sub-Saharan Africa. In 2008, 2.7 million people became infected, a 30-percent fall compared with the peak of HIV's spread 12 years earlier.

IS THERE A CURE? There is currently no cure for HIV, but there is a treatment that can suppress the virus to very low levels. Antiretroviral drugs, a combination of two or three medications that inhibit viral reproduction or stop the virus from fusing with the CD4 T cell, are a lifesaver for millions. But they can also have powerful side effects, including diarrhoea, nausea and cramps, and carry a risk of treatment failure. There are more than 20 antiretroviral drugs today. In poorer countries, 9.5 million people are in immediate need of the therapy, but only four million have access to it.

HOW CAN HIV BE PREVENTED? For sexual intercourse, a latex barrier (a male or female condom) is highly effective. Trials in Africa have shown that male circumcision, which removes mucous cells from the foreskin, can roughly halve the risk of infection for the man, although there is no protection for an uninfected woman. Mother-to-child transmission can be combatted by treating the mother-to-be and the newborn with antiretrovirals. Contamination by blood transfusion is now rare in most countries, thanks to screening of blood donations. Needle exchange programmes, in which a used syringe is swapped for a clean one, can help reduce transmission among drug addicts.

WHAT ABOUT A VACCINE? The search for an HIV vaccine is arguably the toughest challenge of all. Trials of prototype vaccines have shown negligible protection or none at all. However, some encouraging work has been achieved in the lab in identifying antibodies -- natural frontline troops in the immune system -- that could hopefully be primed to recognise the virus. The effort for an HIV-preventing microbicide gel, which could be used in anal or vaginal intercourse, has a similar report card.

SOURCES: UNAIDS; www.avert.org; US National Institutes of Health (NIH); World Health Organisation (WHO); International AIDS Vaccine Initiative (IAVI).

HIV/AIDS in figures
Paris (AFP) July 15, 2010 - Here are the latest estimates of the global HIV/AIDS pandemic, published last November by the UN agency UNAIDS.

Figures are for the end of 2008. An update is expected later this year.

1) TOTAL INFECTIONS IN 2008:

WORLD: Around 33.4 million people living with HIV, in a range of 31.1 million to 35.8 million.

BY REGION:

Sub-Saharan Africa: 22.4 million

South and Southeast Asia: 3.8 million

East Asia: 850,000

Latin America: 2.0 million

North America: 1.4 million

Western and Central Europe: 850,000

Eastern Europe and Central Asia: 1.5 million

Caribbean: 240,000

Middle East and North Africa: 310,000

Oceania: 59,000

2) NEW INFECTIONS IN 2008:

WORLD:

2.7 million people became infected in 2008, unchanged from 2007.

BY REGION:

Sub-Saharan Africa: 1.9 million

South and Southeast Asia: 280,000

East Asia: 75,000

Latin America: 170,000

North America: 55,000

Western and Central Europe: 30,000

Eastern Europe and Central Asia: 110,000

Caribbean: 20,000

Middle East and North Africa: 35,000

Oceania: 3,900

3) AIDS DEATHS IN 2008:

WORLD:

Around two million people died from AIDS-related causes in 2008, unchanged from 2007.

BY REGION:

Sub-Saharan Africa: 1.4 million

South and Southeast Asia: 270,000

East Asia: 59,000

Latin America: 77,000

North America: 25,000

Western and Central Europe: 13,000

Eastern Europe and Central Asia: 87,000

Caribbean: 12,000

Middle East and North Africa: 20,000

Oceania: 2,000

Source: 2009 AIDS Epidemic Update



Share This Article With Planet Earth
del.icio.usdel.icio.us DiggDigg RedditReddit
YahooMyWebYahooMyWeb GoogleGoogle FacebookFacebook



Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


EPIDEMICS
Waterborne infections cost US over 500 million a year: CDC
Washington (AFP) July 14, 2010
Three waterborne diseases account for hospitalizations that cost the US health care system around 539 million dollars a year, the Centers for Disease Control said Wednesday. The CDC said relatively small expenditures to improve water systems and keep swimming pools clean could dramatically reduce the incidence of the three diseases: Legionnaire's disease, cryptosporidiosis and giardiasis. ... read more







EPIDEMICS
Sea Launch Signs Launch Agreement With AsiaSat

PSLV Launch Successful With 5 Satellites Placed In Orbit

ISRO To Launch More Satellites This Year

ILS Successfully Launches The Echostar XV

EPIDEMICS
Team Shows Unity During First Month Of Mars Flight Simulation

Mars Rover Curiosity Spins Its Wheels

Microsoft And NASA Bring Mars Down To Earth Through The WorldWide Telescope

Opportunity Has Two More Drives

EPIDEMICS
Apollo 16: Footsteps Under High Sun

NASA releases videogame, Moonbase Alpha

Man In The Moon Has 'Graphite Whiskers'

India Hopes To Launch Chandrayaan-2 By 2013

EPIDEMICS
Course Correction Keeps New Horizons On Path To Pluto

Scientists See Billions Of Miles Away

System Tests, Science Observations And A Course Correction

Coordinated Stargazing

EPIDEMICS
Recipes For Renegade Planets

First Directly Imaged Planet Confirmed Around Sun-Like Star

VLT Detects First Superstorm On Exoplanet

Earth-Like Planets May Be Ready For Their Close-Up

EPIDEMICS
Musk goes public on divorce

NASA Preparing For DM-2 Test: Now That's Powerful Information

NASA Tests Engine Technology To Assist With Future Space Vehicle Landings

Aerojet Propellant-Saving Xenon Ion Thruster Exceeds 30,000 Hours

EPIDEMICS
China Contributes To Space-Based Information Access A Lot

China Sends Research Satellite Into Space

China eyes Argentina for space antenna

Seven More For Shenzhou

EPIDEMICS
Fascinating Images From A New World

Rosetta Triumphs At Asteroid Lutetia

Rosetta Spacecraft Returns Unique Glimpses Of Asteroid Lutetia

Rockbreaking In Space


The content herein, unless otherwise known to be public domain, are Copyright 1995-2010 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement